Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: The CARD, TITAN, and STOMP trials

ASCO expert Robert Dreicer shares his views on the updates from the CARD, TITAN, and STOMP prostate cancer trials presented at ASCO GU 2020 (3:07).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

14-02-2020 | ASCO GU 2020 | Conference coverage | News

CARD: Favorable metastatic CRPC PROs observed with cabazitaxel

14-02-2020 | ASCO GU 2020 | Conference coverage | News

​​​​​​​STOMP 5-year results confirm potential of metastasis-directed therapy in prostate cancer
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits